SCHEMBL2554480

SCHEMBL2554480

O=Cc1ccc(-c2ccccc2C(=O)O)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 7/20 1.00
KDM4E B2RXH2 5/20 1.00
LMNA P02545 1/20 1.00
ALDH1A1 P00352 5/20 0.73
L3MBTL1 Q9Y468 3/20 0.73
HPGD P15428 2/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
PTP4A3 O75365 1/20 0.55
LDHA P00338 1/20 0.54
LDHB P07195 1/20 0.54
HAO1 Q9UJM8 1/20 0.54
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
MAPT P10636 2/20 0.52
THRB P10828 2/20 0.52
MCL1 Q07820 1/20 0.52
CTDSP1 Q9GZU7 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15331349 0.84 POLB (1.00) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL13809619 0.83 POLB (0.70) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL6428103 0.81 KDM4E (1.00) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL28238005 0.81 POLB (0.68) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL31358829 0.80 AKT1 (0.67) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL2560209 0.78 KDM4E (0.63) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL3038244 0.77 KDM4E (0.63) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL3760167 0.76 PTP4A3 (0.64) POLBKDM4ELMNAL3MBTL1MEN1
SCHEMBL8791374 0.76 KDM4E (0.61) POLBKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL18920689 0.75 KDM4E (0.60) POLBKDM4ELMNAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20050042674-A9 Common ligand mimics: thiazolidinediones and rhodanines TRIAD THERAPEUTICS, INC. 2005-02-24 US disclosed
US-20040009526-A1 Common ligand mimics: thiazolidinediones and rhodanines YU LIN (US) 2004-01-15 US disclosed
WO-2003072033-A2 COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES TRIAD THERAPEUTICS, INC. (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009526-A1 Common ligand mimics: thiazolidinediones and rhodanines GPR65, NR2E3, FGFR3 POLB 4843/4885KDM4E 4288/4885LMNA 4805/4885
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 POLB 2065/4885KDM4E 2503/4885LMNA 3873/4885
US-20050042674-A9 Common ligand mimics: thiazolidinediones and rhodanines GPR65, NR2E3, FGFR3 POLB 4843/4885KDM4E 4288/4885LMNA 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.